| 侍响响,赵 梦,单春明,张逸娴,蒋 煜.重组人干扰素α-2b联合布地奈德雾化吸入对毛细支气管炎患儿炎性因子和康复进程的影响[J].现代生物医学进展英文版,2019,19(16):3192-3195. |
| 重组人干扰素α-2b联合布地奈德雾化吸入对毛细支气管炎患儿炎性因子和康复进程的影响 |
| Effects of Inhalation of Recombinant Human Interferon α-2b Combined with Budesonide on Inflammatory Factors and Rehabilitation Process in Children with Bronchiolitis |
| Received:January 21, 2019 Revised:February 17, 2019 |
| DOI：10.13241/j.cnki.pmb.2019.16.040 |
| 中文关键词: 重组人干扰素α-2b 布地奈德 雾化吸入 毛细支气管炎 炎性因子 |
| 英文关键词: Recombinant human interferon α-2b Budesonide Aerosol inhalation Bronchiolitis Inflammatory factors |
| 基金项目:江苏省卫生计生委2016年度面上科研课题（H20160257） |
| Author Name | Affiliation | E-mail | | SHI Xiang-xiang | Department of Pediatrics, The Affiliated Huaian Hospital of Xuzhou Medical University, Huaian, Jiangsu, 223000, China | xiangxiang2010@yeah.net | | ZHAO Meng | Department of Laboratory Medicine, The Affiliated Huaian Hospital of Xuzhou Medical University, Huaian, Jiangsu, 223000, China | | | SHAN Chun-ming | Department of Pediatrics, BenQ Hospital Affiliated to Nanjing Medical University, Nanjing, Jiangsu, 210019, China | | | ZHANG Yi-xian | Department of Pediatrics, The Affiliated Huaian Hospital of Xuzhou Medical University, Huaian, Jiangsu, 223000, China | | | JIANG Yu | Department of Pediatrics, The Affiliated Huaian Hospital of Xuzhou Medical University, Huaian, Jiangsu, 223000, China | |
|
| Hits: 784 |
| Download times: 539 |
| 中文摘要: |
| 摘要 目的：探讨重组人干扰素α-2b联合布地奈德雾化吸入对毛细支气管炎患儿炎性因子和康复进程的影响。方法：选取于2015年3月至2018年5月间徐州医科大学附属淮安医院收治的102例毛细支气管炎患儿，根据随机数字表法将患儿分为对照组（n=51）和研究组（n=51），对照组给予布地奈德雾化吸入治疗，研究组在对照组基础上联合重组人干扰素α-2b治疗。比较两组患儿临床疗效、临床指标情况，比较两组患儿治疗前、治疗6d后的炎症因子指标，观察两组患儿不良反应发生情况。结果：研究组患儿治疗6d后临床总有效率为92.16%，高于对照组患儿的76.47%（P<0.05）。研究组患儿喘息消失时间、肺部啰音消失时间、退热时间、咳嗽消失时间以及住院时间均短于对照组（P<0.05）。两组患儿治疗6d后白介素-4（IL-4）、白介素-6（IL-6）、肿瘤坏死因子-α（TNF-α）均较治疗前降低，且研究组低于对照组（P<0.05），干扰素-γ（INF-γ）均较治疗前升高，且研究组高于对照组（P<0.05）。两组患儿治疗过程中不良反应发生率比较无统计学差异（P>0.05）。结论：毛细支气管炎患儿采用重组人干扰素α-2b联合布地奈德雾化吸入治疗，疗效显著，可有效改善患儿临床症状，加速康复进程，能有效改善炎性因子水平，不良反应较少，具有一定的临床应用价值。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the effects of inhalation of recombinant human interferon α-2b combined with budesonide on inflammatory factors and rehabilitation process in children with bronchiolitis. Methods: 102 children with bronchiolitis who were admitted to Huaian Hospital Affiliated to Xuzhou Medical University from March 2015 to May 2018 were selected as the research subjects. According to the digital table method, the children were randomly divided into control group (n=51) and research group (n=51). The control group was given budesonide aerosol inhalation therapy, the research group was treated with recombinant human interferon α-2b on the basis of the control group. The clinical efficacy and clinical indicators of the two groups were compared. The inflammatory factors before and 6d after treatment were compared between the two groups, and adverse reactions of the two groups were observed. Results: The total effective rate in the research group was 92.16% at 6d after treatment, which was significantly higher than that in the control group 76.47% (P<0.05). The time of wheezing disappearance, fever abatement, lung rale disappearance, cough disappearance and hospitalization in the research group were shorter than those in the control group (P<0.05). 6d after treatment, the levels of interleukin-4 (IL-4), interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) in both groups were lower than those before treatment, and the research group was lower than the control group (P<0.05). The levels of interferon-γ (INF-γ) were higher than those before treatment, and the research group was higher than the control group (P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). Conclusion: Recombinant human interferon α-2b combined with budesonide aerosol inhalation in the treatment of children with bronchiolitis has a significant effect,it can effectively improve the clinical symptoms of children, accelerate the rehabilitation process, and can effectively improve the level of inflammatory factors, without increasing the incidence of adverse reactions, it has a certain clinical value. |
|
View Full Text
View/Add Comment Download reader |
| Close |
|
|
|
